PMC:7274950 / 10833-11760 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T136","span":{"begin":109,"end":125},"obj":"UBERON:0005409"},{"id":"T137","span":{"begin":155,"end":159},"obj":"UBERON:0000104"},{"id":"T138","span":{"begin":168,"end":174},"obj":"UBERON:0001969"},{"id":"T139","span":{"begin":180,"end":183},"obj":"PR:Q9SMQ6"},{"id":"T140","span":{"begin":201,"end":204},"obj":"PR:Q9SMQ6"},{"id":"T141","span":{"begin":205,"end":215},"obj":"GO:0016234"},{"id":"T142","span":{"begin":221,"end":226},"obj":"UBERON:0002113;CL:1000497"},{"id":"T143","span":{"begin":227,"end":232},"obj":"CL:1000497"},{"id":"T144","span":{"begin":269,"end":278},"obj":"CL:0000653"},{"id":"T145","span":{"begin":411,"end":416},"obj":"UBERON:0000062"},{"id":"T146","span":{"begin":653,"end":661},"obj":"SP_7"},{"id":"T147","span":{"begin":829,"end":837},"obj":"SP_7"},{"id":"T148","span":{"begin":846,"end":854},"obj":"SP_7"},{"id":"T9604","span":{"begin":109,"end":125},"obj":"UBERON:0005409"},{"id":"T14185","span":{"begin":155,"end":159},"obj":"UBERON:0000104"},{"id":"T5065","span":{"begin":168,"end":174},"obj":"UBERON:0001969"},{"id":"T88556","span":{"begin":180,"end":183},"obj":"PR:Q9SMQ6"},{"id":"T99402","span":{"begin":201,"end":204},"obj":"PR:Q9SMQ6"},{"id":"T63298","span":{"begin":205,"end":215},"obj":"GO:0016234"},{"id":"T77613","span":{"begin":221,"end":226},"obj":"UBERON:0002113;CL:1000497"},{"id":"T37944","span":{"begin":227,"end":232},"obj":"CL:1000497"},{"id":"T76245","span":{"begin":269,"end":278},"obj":"CL:0000653"},{"id":"T26927","span":{"begin":411,"end":416},"obj":"UBERON:0000062"},{"id":"T25428","span":{"begin":653,"end":661},"obj":"SP_7"},{"id":"T37112","span":{"begin":829,"end":837},"obj":"SP_7"},{"id":"T85471","span":{"begin":846,"end":854},"obj":"SP_7"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PubTator","denotations":[{"id":"277","span":{"begin":335,"end":343},"obj":"Species"},{"id":"278","span":{"begin":175,"end":183},"obj":"Chemical"},{"id":"279","span":{"begin":55,"end":68},"obj":"Disease"},{"id":"280","span":{"begin":88,"end":104},"obj":"Disease"},{"id":"281","span":{"begin":109,"end":134},"obj":"Disease"},{"id":"286","span":{"begin":855,"end":863},"obj":"Species"},{"id":"287","span":{"begin":653,"end":661},"obj":"Disease"},{"id":"288","span":{"begin":829,"end":837},"obj":"Disease"},{"id":"289","span":{"begin":846,"end":854},"obj":"Disease"}],"attributes":[{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"Tax:9606"},{"id":"A278","pred":"tao:has_database_id","subj":"278","obj":"MESH:C063288"},{"id":"A279","pred":"tao:has_database_id","subj":"279","obj":"MESH:D000795"},{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"MESH:D009437"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"MESH:D012817"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"Tax:9606"},{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"MESH:C000657245"},{"id":"A288","pred":"tao:has_database_id","subj":"288","obj":"MESH:C000657245"},{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T53","span":{"begin":168,"end":174},"obj":"Body_part"},{"id":"T54","span":{"begin":221,"end":232},"obj":"Body_part"},{"id":"T55","span":{"begin":227,"end":232},"obj":"Body_part"},{"id":"T56","span":{"begin":411,"end":416},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"fma_id","subj":"T53","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A54","pred":"fma_id","subj":"T54","obj":"http://purl.org/sig/ont/fma/fma86785"},{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T28","span":{"begin":411,"end":416},"obj":"Body_part"}],"attributes":[{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T61","span":{"begin":55,"end":68},"obj":"Disease"},{"id":"T62","span":{"begin":653,"end":661},"obj":"Disease"},{"id":"T63","span":{"begin":829,"end":837},"obj":"Disease"},{"id":"T64","span":{"begin":846,"end":854},"obj":"Disease"}],"attributes":[{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T119","span":{"begin":19,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T120","span":{"begin":23,"end":24},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T121","span":{"begin":168,"end":174},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T122","span":{"begin":227,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T123","span":{"begin":239,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T124","span":{"begin":310,"end":314},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T125","span":{"begin":310,"end":314},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T126","span":{"begin":411,"end":416},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T127","span":{"begin":424,"end":427},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T128","span":{"begin":463,"end":464},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T27","span":{"begin":180,"end":183},"obj":"Chemical"},{"id":"T28","span":{"begin":201,"end":204},"obj":"Chemical"},{"id":"T29","span":{"begin":310,"end":314},"obj":"Chemical"}],"attributes":[{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_18313"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_18313"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T38","span":{"begin":100,"end":104},"obj":"Phenotype"}],"attributes":[{"id":"A38","pred":"hp_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/HP_0012531"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T5","span":{"begin":180,"end":183},"obj":"GlycoEpitope"},{"id":"T6","span":{"begin":201,"end":204},"obj":"GlycoEpitope"}],"attributes":[{"id":"A5","pred":"glyco_epitope_db_id","subj":"T5","obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"A6","pred":"glyco_epitope_db_id","subj":"T6","obj":"http://www.glycoepitope.jp/epitopes/EP0071"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}

{"project":"LitCovid-sentences","denotations":[{"id":"T78","span":{"begin":0,"end":14},"obj":"Sentence"},{"id":"T79","span":{"begin":15,"end":279},"obj":"Sentence"},{"id":"T80","span":{"begin":280,"end":438},"obj":"Sentence"},{"id":"T81","span":{"begin":439,"end":566},"obj":"Sentence"},{"id":"T82","span":{"begin":567,"end":755},"obj":"Sentence"},{"id":"T83","span":{"begin":756,"end":927},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"1 Conclusions\nERT has a beneficial clinical impact in Fabry disease, as it can relieve neuropathic pain and gastrointestinal symptoms, improve quality of life, reduce plasma lyso-Gb3 levels and clear Gb3 inclusions from renal cells, with a dose-dependent mechanism in podocytes. Evidence, mainly derived from male studies, shows that patients may benefit from early treatment initiation, before major clinical organ damage has developed.\nAfter ERT interruption, a recommencement of therapy does not fully reverse clinical decline resulting from the discontinuation. Home-therapy seems to be the most efficient way to maintain therapy access during the COVID-19 pandemic when possible and correct use of personal protective equipment should be guaranteed. If home-therapy is not available, safe locations and plans that separate COVID-19 and non-COVID-19 patients should be carefully prepared in hospitals and infusion centers."}